Alex Colville

Alex Colville is a leading figure in the longevity biotechnology sector, currently serving as Co-Founder and General Partner at age1. His firm focuses on early-stage investments in biotech companies dedicated to extending healthy human lifespan and addressing age-related diseases, building on his previous experience in establishing the biotech arm of Starbloom Capital. age1+3

With a strong academic foundation, Alex holds a PhD in Genetics from Stanford University, where he specialized in the biology of aging under Dr. Thomas A. Rando. His doctoral research investigated cellular senescence and genetic screens related to aging, culminating in his dissertation 'Dissecting cell death, cellular senescence and aging genetic screens'. afar+2

Prior to his PhD, Alex earned a Bachelor of Science in Chemical Engineering with a minor in Biochemical Engineering from Northeastern University, where he was also the president of the Biomedical Engineering Club and a valedictorian. This engineering background, coupled with his early interest in aging, laid the groundwork for his career at the intersection of science and venture capital. pressherald+2

Alex actively contributes to the scientific community through publications in reputable journals, focusing on topics like cell death, senolytic therapies, and tissue regeneration. His co-authored works, such as 'Death-seq identifies regulators of cell death and senolytic therapies' and 'Transient non-integrative expression of nuclear reprogramming factors promotes tissue regeneration in aged mammals', demonstrate his commitment to advancing the understanding and treatment of aging. nih+3

As an advisor to the TIME Initiative and former Chief of Staff for the Amaranth Foundation, Alex has actively promoted education and research in aging biology. He played a key role in advancing lobbying efforts and supporting moonshot projects within the longevity field, showcasing his dedication to fostering innovation and broader engagement in this area. afar+2